Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Study Finds Renal Arteriosclerosis Is Common in Lupus Nephritis Patients

Mary Beth Nierengarten  |  Issue: February 2021  |  February 16, 2021

CNRI / Science Source

CNRI / Science Source

Renal arteriosclerosis is common in lupus patients with nephritis and occurs two decades earlier than it does in people without lupus nephritis (LN), report investigators in a study that examined the prevalence of renal arteriosclerosis in LN patients compared with healthy controls.1 

The finding suggests that renal arteriosclerosis could be used as a biomarker for early prediction of cardiovascular disease (CVD) risk in LN patients and sub­sequently lead to timely CVD prevention. 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Improving prevention of CVD in patients with LN is needed given the high risk of CVD in these patients. Compared with their healthy controls, patients with LN have a ninefold higher risk of CVD, according to the researchers. (Note: Another study by Garg et al. presented at the 2019 ACR/ARP Annual Meeting showed that severe renal arteriosclerosis at LN diagnosis increased the risk of CVD tenfold compared with patients without severe renal arteriosclerosis. The study also found a correlation between advanced chronic kidney disease and increased cardiovascular risk in patients with LN, with patients with stage 3 or greater chronic kidney disease at a fivefold increased risk of CVD.2) To date, however, biomarkers or tests to predict future CVD are lacking, limiting the ability to identify early who may develop CVD.

Using renal arteriosclerosis as a biomarker or predictor of CVD risk in LN patients is supported by previous studies showing renal arteriosclerosis predicts CVD in other glomerulonephritis diseases, such as IgA nephropathy as well as in renal transplant patients.3-5 Until now, however, no studies have shown a positive association between the presence of renal arteriosclerosis and CVD occurrence in LN patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

One reason may be the lack of emphasis in the current International Society of Nephrology/Renal Pathology Society (ISN/RPS) guidelines on universal reporting using standard criteria for renal arterial changes, according to Shivani Garg, MD, MS, assistant professor of medicine, Division of Rheumatology, University of Wisconsin, Madison. 

The study bore this out. Garg and colleagues also looked at whether renal arteriosclerosis and its severity were under-reported in pathology reports of LN patients and found they were overlooked or missed in >50% of the pathology reports reviewed.

“Clinicians urgently need early predictors of CVD in LN patients to prevent related morbidity and mortality,” state the authors in the study. “Renal arteriosclerosis on pathology reports could be an early pre­dictor of CVD in LN patients.”

Prevalence of Blood Vessel Disease 

Dr. Garg

Dr. Garg

To test their hypothesis that renal arteriosclerosis would occur at a younger age in patients with LN compared with healthy controls, Garg and colleagues reviewed data on 189 LN patients who underwent native renal biopsy between 1994 and 2017 at the University of Wisconsin Hospital and Clinics. Patients ranged in age from 2–79 years (median age of 25 years), and the majority were female (78%) and white (73%). 

Biopsy reports showed that 41% had renal arterial changes (31% had renal arteriosclerosis and 12% had hyaline arteriolosclerosis), and that renal arteriosclerosis increased with age. Overall, one in three patients 60–69 years old had moderate-to-severe sclerosis.

When compared with healthy controls, the onset of any arteriosclerosis in LN patients occurred two decades earlier. Patients with LN aged 30–39 years had comparable renal arteriosclerosis to healthy kidney donors aged 50–59 years (41% vs. 44%), and LN patients aged 40–49 years had comparable renal arteriosclerosis to controls 60–69 years (52% vs. 51%). Patients with LN aged 60-69 years had a fivefold higher prevalence of moderately severe arteriosclerosis compared with age-matched healthy donors (33% vs. 6%). 

The study found age and LN chronicity were independent predictors of renal arterio­sclerosis. Patients with LN older than 30 years had threefold higher odds of developing renal arteriosclerosis than patients younger than 30 (odds ratio [OR] 3.3; confidence interval [CI], 1.3, 9.1; P=0.02), and patients with chronic LN had a fourfold greater odds (OR 4.0; CI, 1.5, 11.6; P=0.01)

Commenting on these findings, Ram Raj Singh, MD, professor of medicine, rheuma­tology, and pathology at the David Geffen School of Medicine, University of California, Los Angeles, emphasizes the need for more research to better understand why some patients with LN develop renal arteriosclerosis. He also notes the need for additional research given the small numbers in the study and the predominance of white patients.

“Because nonwhite patients generally have more severe lupus nephritis and poorer outcomes from lupus, future studies involving diverse patient populations would be needed to further realize the importance of this research,” he says.

The authors note the lack of diversity as a study limitation, and according to Dr. Garg, future research will focus on diverse cohorts and the correlation between renal arteriosclerosis and CVD occurrence.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Cardiovascular diseaseLupus nephritisrenal arterialsclerosis

Related Articles

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

    Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

    October 10, 2016

    The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

    Immunosuppressive Treatment for Lupus in the Next Decade

    April 13, 2011

    It’s time for a new strategy

    A Case of Lupus Podocytopathy

    June 17, 2024

    Kidney involvement is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Collectively termed lupus nephritis, SLE with kidney involvement comes in many subtypes. The current classification by the International Society of Nephrology/Renal Pathology Society (ISN/RPS), however, does not include lupus podocytopathy, which, through various clinical and epidemiologic studies, has recently been…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences